Company news

INmune Bio Inc. news in 2025

INmune Bio Inc.'s news releases, calls and decks from 2025, newest first.

View company

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

December 5, 2025

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

December 1, 2025

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

November 18, 2025

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

October 30, 2025

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

October 23, 2025

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

October 14, 2025

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

September 29, 2025

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

September 15, 2025

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

August 7, 2025

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

July 29, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 24, 2025

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 30, 2025

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

June 30, 2025

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27, 2025

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

June 26, 2025

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

June 10, 2025

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 8, 2025

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

May 5, 2025

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

April 16, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

April 14, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

April 1, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

March 27, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 24, 2025

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

February 11, 2025

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

February 9, 2025

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

January 27, 2025

Calls in 2025

Decks in 2025